



PERSONAL INFORMATION

Name	FABIO FULFARO
Address	VIA ALFONSO BORRELLI 4
Telephone	3349051015
Fax	
E-mail	fabio.fulfaro@unipa.it

Citizenship	Italian
-------------	---------

Birth date	16/05/1968
------------	------------

EDUCATION AND TRAINING

• Date	September 1982- July 1986
• Site	Liceo Scientifico Stanislao Cannizzaro Palermo
• Main Subjects	Latin –Italian-Maths-English
• Qualification	HIGH SCHOOL QUALIFICATION
• National Qualification	Diploma di Scuola Secondaria di Secondo Grado – Liceo Scientifico

• Date	September 1986 – July 1992
• Site	University of Palermo, Facoltà di Medicina e Chirurgia
• Main Subjects	According to study plan
• Qualification	UNIVERSITY DEGREE IN MEDICINE AND SURGERY, SCORE 110/110 CUM LAUDE

• Date	November 1992 – October 1996
• Site	University of Milan – National Cancer Institute
• Main Subjects	Professional traineeship and National qualification test
• Qualification	SPECIALIZATION IN MEDICAL ONCOLOGY

• Date	January 2005-today
• Site	University of Palermo
• Main Subjects	Oncology Gastrointestinal
Qualification	RICERCATORE CONFERMATO

--	--

RELATIONAL SKILLS AND COMPETENCES PERSONAL SKILLS AND COMPETENCES	Past voluntary work experiences have evidenced great relational skills in cooperating with colleagues and in relating with patients. Clinical trials (phase II, phase III) on gastrointestinal neoplasms, supportive care, cancer pain therapy. Clinical expertise in the diagnosis and treatment of cancer. Multidisciplinary evaluation about clinical cases. Use of opioids and other medical drugs in palliative care. Home care.
--	--

MOTHER TONGUE	ITALIAN
---------------	---------

OTHER LANGUAGES

	ENGLISH
• Reading	Good
• Writing	Good
• Speaking	Good

RELATIONAL SKILLS AND COMPETENCES	Past voluntary work experiences have evidenced great relational skills in cooperating with colleagues and in relating with patients.
-----------------------------------	--

TECHNICAL SKILLS AND COMPETENCES	Good
----------------------------------	------

DRIVING LICENSE(S)	B
--------------------	---

ADDITIONAL INFORMATION(S)

Publications

- 1) G. Candido, A. Casuccio, N. Casuccio, **F. Fulfaro**, A. Gentile, R. Oliveri, A. Gullotti: Studio descrittivo sull'andamento della mortalità per cancro nella popolazione di Marsala nell'arco di questo secolo: confronto con i dati regionali e nazionali. *Acta Oncologica*, 15, 87-100, 1994. IF 0
- 2) G. Capri, E. Munzone, E. Tarenzi, **F. Fulfaro** et al.: Optic nerve disturbances: a new form of Paclitaxel neurotoxicity. *J. Natl. Cancer Inst.*, 86, 14: 1099-1101, 1994. IF 15.6
- 3) L. Gianni, E. Munzone, G. Capri, F. Villani, C. Spreafico, E. Tarenzi, **F. Fulfaro** et al.: Paclitaxel in metastatic breast cancer: a trial of two doses by a three hour infusion in patients with disease recurrence after prior therapy with anthracyclines. *J. Natl. Cancer Inst.*, 87, 15: 1169-1175, 1995. IF 15.6
- 4) L. Gianni, E. Munzone, G. Capri, **F. Fulfaro** et al.: Paclitaxel by 3-hour infusion in combination with bolus Doxorubicin in women with untreated metastatic breast cancer: high antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study. *Journal of Clinical Oncology*, 13, 11, 2688-2699, 1995. IF 15.4
- 5) V. Scaioli, A. Caraceni, C. Martini, E. Palazzini, E. Tarenzi, **F. Fulfaro**, E. Munzone: Visual evoked potentials findings in course of paclitaxel doxorubicin combination chemotherapy. Report of a case. *Journal of Neuro-Oncology*, 25: 221-225, 1995. IF
- 6) **F. Fulfaro**, E. Tarenzi, G. Capri, L. Gianni: Considerazioni farmacologiche sull'intensità di dose. *Progressi in Oncologia clinica*, 4: 23-30, 1995 IF 0
- 7) G. Capri, E. Tarenzi, **F. Fulfaro**, L. Gianni: The role of taxanes in the treatment of breast cancer. *Seminars in Oncology*, 23 (1) Suppl. 2 :68-75, 1996
- 8) F. De Conno, **F. Fulfaro**: La sindrome di Trousseau. *Algia*, 3: 12-13, 1997 IF 0
- 9) **F. Fulfaro**, C. Ticozzi, C. Ripamonti: Ruolo del pamidronato disodico nel trattamento delle metastasi ossee. *Quaderni di Cure Palliative*, 5 (3) : 195-201, 1997 IF 0
- 10) L. Licitra, G. Capri, **F. Fulfaro**, C. Grandi, E. Tarenzi, R. Cavina, L. Gianni: Biweekly paclitaxel and cisplatin in patients with advanced head and neck carcinoma. A phase II trial. *Annals of Oncology*, 8 : 1157-1158, 1997 IF 4.8
- 11) C. Ripamonti, **F. Fulfaro**, D. Polastri, et al.: Pain relief and sclerosis of bone metastasis in a patient with breast cancer treated with tamoxifen, radiotherapy and pamidronate disodium: Which treatment helped ? *Journal of Pain and Symptom Management*, 16: 73-76, 1998 IF 2.3
- 12) **F. Fulfaro**, V. Quagliuolo, F. De Conno, C. Ripamonti: Carcinoid somatostatinoma of the duodenum. *European Journal of Surgical Oncology*, 24: 601-604, 1998 IF 2.0
- 13) C. Ripamonti, **F. Fulfaro**, E. Bruera: Dyspnoea in patients with advanced cancer: incidence, causes and treatments. *Cancer Treatment Reviews*, 24: 69-80, 1998 IF 4.5

- 14) C. Ripamonti, E. Zecca, C. Brunelli, **F. Fulfaro**, et al.: A randomized controlled clinical trial to evaluate the effects of zinc sulphate on cancer patients with taste alterations caused by head and neck irradiation. *Cancer*, 82: 1938-1945, 1998 IF 4.6
- 15) A. Casuccio, N. Casuccio, **F. Fulfaro**, B. Pedalino, A. Gullotti: Seroepidemiologic research and hygienic-sanitary evaluation about human and animal brucellosis in Palermo province. *L'Igiene Moderna*, 109: 107-120, 1998 IF 0
- 16) C. Ripamonti, **F. Fulfaro**, C. Ticozzi, A. Casuccio, F. De Conno: Role of pamidronate disodium in the treatment of metastatic bone disease. *Tumori*, 84: 442-455, 1998 IF 0.8
- 17) **F. Fulfaro**, A. Casuccio, C. Ticozzi, e C. Ripamonti: The role of bisphosphonates in the treatment of painful metastatic bone disease: a review of phase III trials. *Pain*, 78: 157-169, 1998. IF 5.2
- 18) C. Ripamonti, **F. Fulfaro**: Ruolo dello zinco nel trattamento delle alterazioni gustative. *Quaderni di Cure Palliative*, 6: 175-179, 1998. IF 0
- 19) C. Ripamonti, **F. Fulfaro**: Taste alterations in cancer patients. *Journal of Pain and Symptom Management*, 16: 349-351, 1998. IF 2.3
- 20) C. Ripamonti, A. Votta, **F. Fulfaro**: Analgesia controllata del paziente (PCA). Revisione della letteratura. *Quaderni di cure palliative*, 6: 225-235, 1998. IF 0
- 21) S. Mercadante, **F. Fulfaro**: Alternatives to oral opioids for cancer pain. *Oncology*, 13: 215-225, 1999. IF 1.1
- 22) C. Ticozzi, **F. Fulfaro**, C. Ripamonti: Ruolo del pamidronato disodico nel trattamento delle metastasi ossee: revisione aggiornata della letteratura. *Rivista Italiana di Cure Palliative*, 1: 225-229, 1999. IF 0
- 23) S. Mercadante, **F. Fulfaro**, A. Casuccio, L. Barresi: Investigation of an opioid response categorization in advanced cancer patients. *Journal of Pain and Symptom Management*, 18: 347-352, 1999. IF 2.3
- 24) **F. Fulfaro**, C. Ripamonti: Cause e meccanismi del dolore toracico: dolori della parete toracica, dolori mediastinici, dolori diaframmatici, plessopatia brachiale. *Quaderni di Cure Palliative*, 7: 253-261, 1999. IF 0
- 25) S. Mercadante, A. Casuccio, S. Pumo, **F. Fulfaro**: Factors influencing the opioid response in advanced cancer patients with pain followed at home: the effects of age and gender. *Supportive Care in Cancer*, 8: 123-130, 2000. IF 2.1
- 26) S. Mercadante, L. Calderone, P. Villari, R. Serretta, M. Sapio, A. Casuccio and **F. Fulfaro**: The use of pilocarpine in opioid-induced xerostomy. *Palliative Medicine*, 14: 529-531, 2000. IF 1.6
- 27) C. Ripamonti and **F. Fulfaro**: Malignant bone pain: pathophysiology and treatments. *Current Review of Pain*, 4: 187-196, 2000. IF 0
- 28) S. Mercadante, G Di Silvestre, F Fulfaro. Assistenza Domiciliare a bambini nella fase terminale della malattia neoplastica. *Rivista Italiana di Cure Palliative*, 2, 85-88, 2000 IF 0
- 29) S. Mercadante, A. Casuccio and **F. Fulfaro**: The course of symptom frequency and intensity in advanced cancer patients

- followed at home. Journal of Pain and Symptom Management, 20: 104-112, 2000. IF 2.3
- 30) S. Mercadante, A. Casuccio, S. Pumo and **F. Fulfaro**: Opioid responsiveness-primary diagnosis relationship in advanced cancer patients followed at home. Journal of Pain and Symptom Management, 20: 27-34, 2000. IF 2.3
 - 31) S. Mercadante and **F. Fulfaro**: An unusual coma after therapy for bone pain. Journal of Pain and Symptom Management, 19: 323-324, 2000. IF 2.3
 - 32) S. Mercadante, **F. Fulfaro**, A. Casuccio: The impact of home palliative care on symptoms in advanced cancer patients. Supportive Care in Cancer, 8:307-310, 2000.
 - 33) S. Mercadante, L. Barresi, A. Casuccio and **F. Fulfaro**: Gastrointestinal bleeding in advanced cancer patients. Journal of Pain and Symptom Management, 19: 160-162, 2000.
 - 34) S. Mercadante, **F Fulfaro**, M Dabbene: Methadone in treatment of tenesmus not responding to morphine escalation. Supportive Care in Cancer, 9: 129-130, 2001. IF 2.1
 - 35) S. Mercadante, **F Fulfaro**, A. Casuccio: Pattern of drug use by advanced cancer patients followed at home. Journal of Palliative Care, 17: 37-40, 2001. IF 0.88
 - 36) Mercadante S, Casuccio A, **Fulfaro F**, et al. Switching from morphine to methadone to improve analgesia and tolerability in cancer patients: a prospective study. Journal of Clinical Oncology, 19: 2898-2904, 2001. IF 15.4
 - 37) Mercadante S, **Fulfaro F** and Casuccio A. The use of corticosteroids in home palliative care. Supportive Care in Cancer, 9: 386-389, 2001. IF 2.1
 - 38) Mercadante S, Villari P, **Fulfaro F**. Gabapentin for opioid-related myoclonus in cancer patients. Support Care Cancer, 9: 205-206, 2001 IF 2.1
 - 39) Ripamonti C, **Fulfaro F**. Pathogenesis and pharmacological treatment of bone pain in skeletal metastases. Q J Nucl Med, 45: 65-77, 2001 IF 2.0
 - 40) Mercadante S, Villari P, **Fulfaro F**. Rifampicin in opioid-induced itching. Support Care Cancer, 9: 467-468, 2001 IF 2.1
 - 41) I. Zanna, G. Agosta, V. Bazan, C. Tubiolo, M. Migliavacca, S. Corsale, A. Amato, M. R. Valerio, G. Cicero, S. Bonventre, C. Arcara, G. Badalamenti, E. Bajardi, A. Crosta, **F. Fulfaro**, A. Russo "I carcinomi ereditari della mammella: biologia e clinica." Endocrinochirurgia, attualità e prospettive. Giuseppe De Nicola editore, pp 263-271, 2001 IF 0
 - 42) **Fulfaro F.**, Valerio M. R, Faldetta N, Bajardi E, Armata M. G., Cicero G , Badalamenti G Arcara C, Rinaldi G., Crosta A, Gebbia N., Rini GB Utilizzo dell'acido zoledronico nella malattia ossea metastatica. Oncologia ed Ematologia moderne. 4 (2) pag 9-17, 2002 IF 0
 - 43) V. Bazan, M. Migliavacca, I. Zanna, C. Tubiolo, S. Corsale, V Calò, A Amato, P Cammareri, F Latteri, N. Grassi, **F Fulfaro**, R Porcasi, M. Macaluso, M. Morello, RB Nuara, G Dardanoni, S Salerno, M. R. Valerio, L Dusonchet, A Gerbino N. Gebbia, R. M. Tomasino, A. Russo. Dna ploidy and S-phase fraction, but not p-53 or NM23-H1 expression, predict outcome in colorectal cancer

- patients. Result of a 5-year prospective study. *J Cancer Res Clin Oncol* 128:650-658, 2002 IF 2.3
- 44) Mercadante S, **Fulfaro** F, Casuccio A. Pain mechanisms involved and outcome in advanced cancer patients with possible indications for celiac plexus block and superior hypogastric plexus block. *Tumori*. 88(3):243-5, 2002 IF 0.8
- 45) Mercadante S, Villari P, Ferrera P, Casuccio A, **Fulfaro** F. Rapid titration with intravenous morphine for severe cancer pain and immediate oral conversion. *Cancer*. 95(1):203-8, 2002. IF 4.6
- 46) Mercadante S, **Fulfaro** F, Casuccio A. A randomised controlled study on the use of anti-inflammatory drugs in patients with cancer pain on morphine therapy: effects on dose-escalation and a pharmacoeconomic analysis. *Eur J Cancer*. 38(10):1358-63, 2002. IF 4.4
- 47) **F.Fulfaro**, S Siragusa, C.Arcara et al. Trombosi e Cancro: Principi di profilassi e terapia. *Oncologia ed Ematologia moderne* 5 (1), 31-40, 2003 IF 0
- 48) S. Mercadante, M Bianchi, P Villari, P Ferrera, A Casuccio, **F Fulfaro**, Gebbia V. Opioid plasma concentration during switching from morphine to metadone: preliminary data. *Supp Care Cancer May*;11(5):326-31, 2003 IF 2.1
- 49) M. Migliavacca, V.Bazan, S Corsale, A.Amato, V Agnese, V Calò, P Cammarieri, S Cascio, G La Rocca, PS Sisto, MS Totaro, G Badalamenti, A Crosta, **F Fulfaro** et al. Clinical implications of genetic studies in hereditary breast carcinomas. *Acta Chir Med* 19, 1, 5-9, 2003 IF 0
- 50) **F.Fulfaro**, L. Crosta, MR Valerio et al. Neoplasie del Colon Retto: si possono prevenire? *Consensus*, 3 (1), 5-26, 2003 IF 0
- 51) Dieli F, Gebbia N, Poccia F, Cacciamo N, Montesano C, **Fulfaro** F et al Induction of-lymphocyte effector functions by bisphosphonate zoledronic acid in cancer patients in vivo. *Blood*, 102: 2310 – 2311, 2003 IF 10.8
- 52) **F.Fulfaro**, MR Valerio, G. Badalamenti et al. Antitlastic Drug Combination with Ifosfamide: an update. *Oncology* 65 Suppl 2:21-30, 2003 IF 1.2
- 53) Mercadante S, Fusco F, Valle A, **Fulfaro** F, Casuccio A, Silvestro S, Donelli. E. Factors involved in gastrointestinal bleeding in advanced cancer patients followed at home. *Support Care Cancer*. 12(2):95-8, 2004 IF 2.1
- 54) **Fulfaro** F, Bajardi E, Badalamenti G et al. La terapia medica adiuvante nel carcinoma del colon: un update della letteratura. *Oncologia ed Ematologia moderne* 6 (2), 54-62, 2004 IF 0
- 55) Mercadante S and Fulfaro F. World Health Organization guidelines for cancer pain: a reappraisal. *Ann Oncol* 16, Suppl 4, 32-34, 2005 IF 4.8
- 56) Siragusa S, Arcara C, Malato A, Anastasio R, Valerio MR, Fulfaro F, Lo Coco L, Grimaudo S, Bajardi G, Abbadessa V, Gebbia N. Home therapy for deep vein thrombosis and pulmonary embolism in cancer patients. *Ann Oncol* 16, Suppl 4, 36-40, 2005 4.8
- 57) Arcara C, Gebbia N, Fulfaro F. Carcinoma squamocellulare del pene localmente avanzato: associazione tra risposta clinica e modificazione dei livelli di ferritina sierica. *Casi Clinici in*

- Oncologia 13, 15-19, 2005 IF 0
- 58) Fulfaro F, Badalamenti G, Bajardi E et al. Utilizzo dei farmaci adiuvanti nel dolore da cancro. *Oncologia ed Ematologia moderne* 1, 48-55, 2005 IF 0
 - 59) Fulfaro F, Badalamenti G, Arcara C et al. Utilizzo dell'octreotide nell'epatocarcinoma: case report e review della letteratura. *Oncologia ed Ematologia moderne* 2, 27-29, 2005 IF 0
 - 60) Leto G, Badalamenti G, Arcara C, Crescimanno M, Flandina C, Tumminello FM, Incorvaia L, Gebbia N and Fulfaro F. Effects of Zoledronic Acid on proteinase plasma levels in patients with bone metastases. *Anticancer Research*, 26,(1A),23-26, 2006 IF 7.6
 - 61) Leto G, Incorvaia L, Badalamenti G, Arcara C, Fulfaro F, Tumminello FM, Flandina C, Crescimanno M, Gebbia N. Tumor markers in urogynecological tumors. *La Tunisie Medicale* 83, 12, 28, 2005 IF 0
 - 62) Correale P, Fulfaro F, Marsili S et al. Gemcitabine plus Oxaliplatin folinic acid and 5Fluorouracil (FOLFOX 4) in patients with advanced gastric cancer. *Cancer Chemother Pharmacol* 56 (6),563-568, 2005 IF 2.0
 - 63) Napoli P, Corradino B, Badalamenti G, Tripoli M, Vieni S, Fulfaro F, Cordova A, Moschella F. Surgical treatment of extravasation injures. *Journal of Surgical Oncology*, 91, 264-269, 2005 IF 2.3
 - 64) GOIM Collaborative Group Modulation of 5-fluorouracil as adjuvant systemic chemotherapy in colorectal cancer: the IGCS-COL multicentre, randomised, phase III study. *Brit J Cancer* ;93(8):896-904, 2005 IF 4.6
 - 65) Fulfaro F, Leto G, Badalamenti G et al. The use of zoledronic acid in patients with bone metastases from prostate carcinoma: Effect on analgesic response and bone metabolism biomarkers. *Journal of Chemotherapy* 17, 5, 555-559, 2005 IF 0.9
 - 66) Valerio MR, Tagliaferri P, Raspagliesi F, Fulfaro F et al. A phase II study of pegylated liposomal doxorubicin, oxaliplatin and cyclophosphamide as second line treatment in relapsed ovarian cancer. *Int J Gynecol Cancer* 16, Suppl 1, 79-85, 2006 IF 1.4
 - 67) Mercadante S, Porzio F, Ferrera P, Fulfaro F et al. Low morphine doses in opioid naive cancer patients with pain. *J Pain Symptom Management* 31 (3), 242-247, 2006 IF 2.3
 - 68) Russo A, Corsale S, Agnese V, Macaluso M, Cascio S, Bruno L, Dardanoni G, Valero MR, Vieni S, Fulfaro F, Tomasino MR, Gebbia N. TP53 mutations and S-Phase fraction but not DNA ploidy are independent prognostic indicators in laryngeous squamous cell carcinoma. *J Cell Physiol* 206 (1), 181-188, 2006 IF 3.6
 - 69) Correale P, Fulfaro F, Marsili S, Cicero G, Bajardi E, Intrivici C, Vuolo G, Carli AF, Caraglia M, Del Prete S, Greco E, Gebbia N, Francini G. Gemcitabine (GEM) plus oxaliplatin, folinic acid, and 5-fluorouracil (FOLFOX-4) in patients with advanced gastric cancer. *Cancer Chemother Pharmacol*. 2005 Dec;56(6):563-8. 2005 IF 2.5
 - 70) Gargano G, Agnese V, Calo V, Corsale S, Augello C, Bruno L, La Paglia L, Gullo A, Ottini L, Russo A, Fulfaro F, Rinaldi G, Crosta A, Cicero G, et al Detection and quantification of mammaglobin in the blood of breast cancer patients: can it be useful as a potential clinical

marker? Preliminary results of a GOIM (Gruppo Oncologico dell'Italia Meridionale) prospective study. *Ann Oncol.* 2006 Jun;17 Suppl 7:vii41-vii45. IF 4.8

- 71) Verderame F, Russo A, Di Leo R, Badalamenti G, Santangelo D, Cicero G, Valerio MR, Gulotta G, Tomasello G, Gebbia N, Fulfaro F. Gemcitabine and oxaliplatin combination chemotherapy in advanced biliary tract cancers. *Ann Oncol.* 2006 Jun;17(suppl_7):vii68-vii72. IF 4.8
- 72) Arcara C, Fulfaro F, Badalamenti G, Gebbia N, Arcara M. A case of squamocellular uterine cervix carcinoma metastatic to the skin with enterocutaneous fistula. *Tumori.* 2006 May-Jun;92(3):264-6.
- 73) Cipolla C, Fulfaro F, Sandonato L, Fricano S, Pantuso G, Grassi N, Vieni S, Valerio MR, Lo Dico R, Gebbia N, Latteri MA. Clinical presentation and treatment of gastrointestinal stromal tumors. *Tumori.* 2006 Jul-Aug;92(4):279-84.
- 74) Cicero G, Fulfaro F, Caraceni A, Arcara C, Badalamenti G, Intrivici C, Gebbia N. A case of guillain-barre syndrome in a patient with non small cell lung cancer treated with chemotherapy. *J Chemother.* 2006 Jul;18(3):325-7.
- 75) Mercadante SL, Berchovich M, Casuccio A, Fulfaro F, Mangione S. A prospective randomized study of corticosteroids as adjuvant drugs to opioids in advanced cancer patients. *Am J Hosp Palliat Care.* 2007 Feb-Mar;24(1):13-9.
- 76) Mercadante S, Fulfaro F. Management of painful bone metastases. *Curr Opin Oncol* 2007, 19 (4), 308-314 IF 3.7
- 77) Di Liberto C, Caroprese M, Pizzo G, Compilato D, Fulfaro F et al. Oral complications in patients with head and neck cancer after radio-chemotherapy. Mucositis and Xerostomia. *Recenti Progressi in Medicina*, 2007, 34 (5): 302-314 IF 0
- 78) Mercadante S, Porzio G, Fulfaro F et al. Switching from transdermal drugs: an observational "N of 1 " study of fentanyl and buprenorphine. *J Pain Symptom Manage* 2007, 34 (5):532-538 IF 2.3
- 79) Dieli F, Vermijlen D, Fulfaro F et al. Targeting human gamma delta T cells with zoledronate and interleukin 2 for immunotherapy of hormone refractory prostate cancer. *Cancer Res* 2007, 1,67 (15), 7450-7457 IF 7.6
- 80) Gargano G, Calcara D, Corsale S, Agnese V, Intrivici C, Fulfaro F et al. Aberrant methylation within RUNX3 CpG island associated with the nuclear and mitochondrial microsatellite instability in sporadic gastric cancers. Result of a GOIM (Gruppo Oncologico dell'Italia Meridionale) prospective study. *Ann Oncol* 2007, suppl 6,vi 103-109 IF 4.8
- 81) Badalamenti G, Rodolico V, Fulfaro F et al. Gastrointestinal stromal tumors (GISTs): focus on histopathological diagnosis and biomolecular features. *Ann Oncol* 2007, 18, suppl 6 , vi 136-140 IF 4.8
- 82) Campisi G, Di Fede O, Musciotto A, Lo Casto A, Lo Muzio L, Fulfaro F et al. Bisphosphonate-related osteonecrosis of the jaw (BRONJ): run dental management design and issues in diagnosis. *Ann Oncol* 2007 18, suppl 6, vi 168-172 IF 4.8
- 83) Mercadante S, Porzio G, Ferrera P, Fulfaro F, Aielli F, Verna L, Villari P, Ficorella C, Gebbia V, Riina S, Casuccio A, Mangione S. Sustained-release oral

morphine versus transdermal fentanyl and oral methadone in cancer pain management. Eur J Pain. 2008 Nov;12(8):1040-6. Epub 2008 Mar 18 IF 3.7.

- 84) Tumminello FM, Badalamenti G, Incorvaia L, Fulfaro F, D'Amico C, Leto G. Serum interleukin-6 in patients with metastatic bone disease: correlation with cystatin C. Med Oncol. 2009;26(1):10-5. Epub 2008 May 7.
- 85) Vincenzi B, Santini D, Galluzzo S, Russo A, Fulfaro F, Silletta M, Battistoni F, Rocci L, Zobel BB, Adamo V, Dicuonzo G, Tonini G. Early magnesium reduction in advanced colorectal cancer patients treated with cetuximab plus irinotecan as predictive factor of efficacy and outcome. Clin Cancer Res. 2008 Jul 1;14(13):4219-24. IF 6.2
- 86) Russo A, Rizzo S, Fulfaro F, Adamo V, Santini D, Vincenzi B, Gebbia N, Carrea I. Gemcitabine-based doublets versus single-agent therapy for elderly patients with advanced nonsmall cell lung cancer: a Literature-based Meta-analysis. Cancer. 2009 Feb 20 IF 4.6
- 87) Russo A, Bronte G, Fulfaro F, Cicero G, Adamo V, Gebbia N, Rizzo S. Bortezomib: a new pro-apoptotic agent in cancer treatment. Curr Cancer Drug Targets. 2010 Feb;10(1):55-67.
- 88) Tumminello FM, Badalamenti G, Fulfaro F, Incorvaia L, Crescimanno M, Flandina C, Sepporta MV, Leto G. Serum follistatin in patients with prostate cancer metastatic to the bone. Clin Exp Metastasis. 2010 Dec;27(8):549-55
- 89) Mercadante S, Tirelli W, David F, Arcara C, Fulfaro F, Casuccio A, Gebbia V. Morphine versus oxycodone in pancreatic cancer pain: a randomized controlled study. Clin J Pain. 2010 Nov-Dec;26(9):794-7.
- 90) Rizzo S, Bronte G, Fanale D, Corsini L, Silvestris N, Santini D, Gulotta G, Bazan V, Gebbia N, Fulfaro F, Russo A. Prognostic vs predictive molecular biomarkers in colorectal cancer: is KRAS and BRAF wild type status required for anti-EGFR therapy? Cancer Treat Rev. 2010 Nov;36 Suppl 3:S56-61
- 91) Siragusa S, Armani U, Carpenedo M, Falanga A, Fulfaro F, Imberti D, Laurora R, Molinari AC, Prisco D, Silingardi M, Verso M, Visonà A; Italian Society for Haemostasis and Thrombosis. Prevention of venous thromboembolism in patients with cancer: guidelines of the Italian Society for Haemostasis and Thrombosis (SISSET)(1). Thromb Res. 2012 May;129(5):e171-6.
- 92) Mercadante S, Adile C, Torta R, Varetto A, Fulfaro F, Giarratano A, Casuccio A. Meaningful cut-off pain intensity for breakthrough pain changes in advanced cancer patients. Curr Med Res Opin. 2013 Jan;29(1):93-7
- 93) Badalamenti G, Incorvaia L, Provenzano S, Bronte G, Leto G, Fulfaro F, Maltese G. Lenograstim in preventing chemotherapy-induced febrile neutropenia in patients with soft tissue sarcoma. Anticancer Res. 2013 Feb;33(2):679-84.

--	--

Ai sensi del DLgs.30 giugno 2003 n.196,il sottoscritto presta il proprio consenso al Trattamento ed alla comunicazione dei propri dati personali.

Data 01/07/16

 Firma Fabio Fulfaro
AZIENDA OSPEDALIERA UNIVERSITARIA
POLICLINICO DI PALERMO
UO ONCOLOGIA MEDICA
Dr Fabio Fulfaro
Specialista in Oncologia
Cod. ENPAM 300186356S
Iscri. Ordine dei Medici 12518 PA